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Abstract A boy presented at age 2.5 years with mild left
ventricular hypertrophy and mild myopathy. Hypertro-
phic cardiomyopathy progressed relentlessly, leading to
death at age 16 years shortly before planned heart
transplantation. During the course of the disease, his
mother developed severe dilated cardiomyopathy and
died of its complications at 46 years of age. The com-
bination of myopathy and cardiomyopathy, the bio-
chemical and electron microscopy ﬁndings in a muscle
biopsy, and the pedigree suggested Danon disease (MIM
300257), an X-linked lysosomal storage disorder caused
by deﬁciency of lysosome-associated membrane protein-
2 (LAMP2). The diagnosis was conﬁrmed by the iden-
tiﬁcation of a novel mutation, G138A, in the
LAMP2gene, leading to the premature stop codon
W46X. Conclusion: Early diagnosis of Danon disease is
important for genetic counselling and timely cardiac
transplantation, the only eﬀective therapeutic option.
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Introduction
Danon disease (MIM 300257) is a rare X-linked dis-
order characterised by cardiomyopathy, skeletal
myopathy, and mental retardation. The myopathy is
generally mild and the mental retardation variable, but
cardiomyopathy dominates the clinical picture and
determines the outcome. Mutations in the LAMP2-
gene on Xq24 have been shown to be responsible for
the disease, the cellular pathogenesis being caused by a
deﬁciency of lysosome-associated membrane protein-2
(LAMP2). This explains the lysosomal storage that
occurs in this disorder, which includes elevated muscle
glycogen in spite of normal a-glucosidase (acid maltase)
activity. The pathological hallmark of the disease is
cytoplasmic vacuoles containing autophagic material
and glycogen in skeletal and cardiac muscle cells.
Understanding of Danon disease in man has been ai-
ded by the availability of an animal model, the lamp2-
deﬁcient mouse; lamp2-deﬁcient mice have reduced
weight and increased mortality, and autophagic vacu-
oles accumulate in many tissues including skeletal and
heart muscle, liver, pancreas, spleen, and kidney. In
hepatocytes, the autophagic degradation of long-lived
proteins is severely impaired, cardiac myocytes are ul-
trastructurally abnormal and heart contractility is se-
verely reduced [19,23].
This report of a family with Danon disease demon-
strates the typical course of the disease and the diﬃculty
of determining the right moment for cardiac transplan-
tation.
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Case report
The mother of the patient suﬀered from severe dilated
cardiomyopathy with atrial ﬁbrillation. The onset of
symptoms was at age 37 years and an endomyocardial
biopsy showed intracellular vacuoles which were fre-
quently located near the nuclei. A granular pigment was
also scattered over the whole specimen. Light micros-
copy showed localised focal ﬁbrosis of the endocardium
and widespread myocardial necrosis of both ventricles.
There was marked coronary sclerosis. The mother died
at age 46 years, during evaluation for cardiac trans-
plantation, due to intimal dissection of the right coro-
nary artery on cardiac catheterisation. Autopsy was not
done and a diagnosis of Danon disease was not sus-
pected during her lifetime. The maternal family is of
Swiss origin. Family history showed that the mother had
an older brother and a younger sister who are both
healthy, and did not indicate further aﬀected individu-
als.
The patient, who had an older sister and a younger
brother, both of whom are healthy, was born at term
after a normal pregnancy. Fetal movements were re-
ported to be normal. Neonatal adaptation and gross
motor development were also normal. At age 2.5 years
the patient presented with mild tiredness and attacks of
abdominal pain. He also had diﬃculty standing up after
falls. Abdominal symptoms disappeared after some
months but the mild exercise intolerance (NYHA II)
persisted. Clinical examination of the heart was normal.
Initial ECG was normal and echocardiography at age 3
years showed only mild thickening of the left ventricular
posterior wall. Serum creatine kinase was elevated at
943 U/l (normal <196 U/l).
He received speech and language therapy for a
moderate delay in expressive speech development at age
7 years. There were also mild learning disabilities with
an average performance at primary school.
Echocardiography over time showed a continuous
thickening of the myocardial wall, which resulted in a
severe concentric hypertrophy of both ventricles without
obstruction of the left ventricular outﬂow tract (Fig. 1).
Chest radiography showed severe cardiomegaly (Fig. 2).
At age 10 years he complained of recurrent palpita-
tions that were controlled with atenolol. ECG at age 11
years demonstrated pre-excitation with a left bundle
branch block pattern (Fig. 3). Holter monitoring
showed runs of nonsustained AV re-entrant tachycardia.
Physical examination 15 years of age revealed a
prominent left ventricular impulse and a grade 3 ejection
systolic murmur at the left sternal border. Neurological
examination was normal. Congestive heart failure pro-
gressed rapidly at age 16 years and the patient suﬀered
from recurrent fainting. A left ventricular assist device
was implanted as a bridge to transplantation [9].
Unfortunately, during the 4th month subsequent to this,
the patient died of sepsis. Consent for an autopsy was
not given.
Materials and Methods
Enzyme assays
In muscle, glycogen content and activities of a-gluco-
sidase (EC 3.2.1.20) and phosphorylase (EC 2.4.1.1)
were determined according to Hers [14]. The activities
Fig. 1 Echocardiography at age 11 years. Parasternal short axis
view showing severe concentric hypertrophy of the left ventricle
(arrows)
Fig. 2 Chest X-ray ﬁlm taken at age 14 years showing severe
cardiomegaly
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of phosphofructokinase (EC 2.7.1.11) and phosphory-
lase b-kinase (EC 2.7.1.38) were determined according
to Beutler [4] and Huijing [16], respectively, and the
mean outer chain length of glycogen was determined
by a glycogen-iodine-spectrum as described by Kris-
man [17]. In serum, leukocytes, and ﬁbroblasts, activ-
ities of the lysosomal enzymes a-iduronidase (EC
3.2.1.76), a-fucosidase (EC 3.2.1.51), a-galactosidase
(EC 3.2.1.22), b-galactosidase (EC 3.2.1.23), b-gluco-
sidase (EC 3.2.1.21), b-glucuronidase (EC 3.2.1.31),
and b-hexosaminidase (EC 3.2.1.50) were determined
ﬂuorimetrically according to Galjaard [12], while acid
phosphatase (EC 3.1.3.2) and arylsulfatase A (EC
3.1.6.8) activities were determined according to Beutler
et al. [5] and Baum et al. [2], respectively.
Molecular analysis
Primers were designed for the ampliﬁcation of exons 1–
8, 9a and 9b of LAMP2 (chromosome Xq24) [11]. PCR
products were subjected to single strand conformational
polymorphism (SSCP) analysis following standard pro-
tocols. For exons showing a band shift in SSCP, direct
sequencing was performed using an ABI Prism 310 se-
quencer.
Results
Morphological ﬁndings
Skeletal muscle biopsy of the vastus lateralis muscle was
done at age 11 years. Light microscopy revealed central
vacuoles with irregular margins. Only a small propor-
tion of muscle ﬁbres were atrophic. One region con-
tained inﬂammatory inﬁltrates. Immunohistochemical
staining of the central vacuoles was positive for laminin,
dystrophin-associated glycoprotein, and dystrophin.
Electron microscopy demonstrated large amounts of
free glycogen between the myoﬁbrillar bundles and
subsarcolemmally. Glycogen was also present in lyso-
somes. Numerous cytoplasmic, cylinder-shaped struc-
tures were present, their major axes being oriented along
the myoﬁbrils (Fig. 4). Their content was highly poly-
morphic. These structures are typical of Danon disease
and are believed to represent autophagic vacuoles.
Fig. 3 12-lead ECG obtained at age 11 years. Sinus rhythm with
signs of severe left ventricular hypertrophy, left bundle branch
block, and delta wave (arrows)
Fig. 4 Skeletal muscle: (a) autophagic vacuoles (EM ·3150); (b) a
diﬀerent orientation reveals the tubular shape of the autophagic
vacuoles (EM ·3150); (c) Excessive and diﬀuse accumulation of
glycogen visible as ﬁne granules (arrows) (EM ·12500)
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Biochemical ﬁndings
Muscle glycogen content was slightly elevated (2.8%,
reference range 0.7%–2.0%) but the glycogen outer
chain length was normal. Normal activity of a-glucosi-
dase, phosphorylase, phosphofructokinase, phosphory-
lase b-kinase, and the normal outer chain length of
glycogen excluded glycogen storage diseases II (Pompe
disease), III (debranching enzyme deﬁciency), V
(McArdle disease), VII (Tarui disease), and IX (phos-
phorylase b-kinase deﬁciency).
The following enzymes were consistently elevated in
serum, the values given being those at age 11 years:
creatine kinase 1521 U/l (normal <196 U/l), creatine
kinase isoenzyme MB 28 U/l (<25 U/l), alkaline phos-
phatase 265 U/l (<105 U/l), aspartate aminotransferase
378 U/l (<29 U/l), alanine aminotransferase 413 U/l
(<27 U/l), and lactate dehydrogenase 4158 U/l
(<657 U/l).
At age 15 years, several acid hydrolases were mea-
sured in serum and leukocyte homogenate: activities of
a-fucosidase, a-galactosidase, b-galactosidase, b-glucu-
ronidase, and b-hexosaminidases A and B were within
the respective reference ranges in serum and near the
lower ends of the reference ranges in leukocytes. In
cultured skin ﬁbroblasts, acid phosphatase, arylsulfatase
A, a-fucosidase, a-galactosidase, b-galactosidase, a-glu-
cosidase, b-glucosidase, b-glucuronidase, b-hexosamini-
dase A + B, and a-iduronidase activities were all within
the respective reference ranges.
Molecular ﬁndings
SSCP analysis showed a band shift in the PCR product
of LAMP2exon 2 from the patient (Fig. 5). Subsequent
direct sequencing on an ABI Prism 310 sequencer de-
tected a 138 G ﬁ A point mutation (W46X) which re-
sulted in a premature stop codon being introduced at
codon 46. Assuming that mRNA containing the pre-
mature stop codon escaped nonsense-mediated decay, it
would direct the synthesis of a truncated LAMP2 pro-
tein lacking a major part of the carboxyl terminal do-
main, including the whole transmembrane region. The
mutation was not present in the patient’s healthy sister
and brother. There was no maternal material available
for investigation.
Discussion
The characteristics of Danon disease have been de-
scribed in a number of case reports [3, 6, 7, 8, 10, 13, 21,
24, 25,26]. The typical clinical picture includes childhood
onset, male predominance (1.8:1) [26], cardiomyopathy,
mild myopathy, and mental retardation of variable de-
gree. Cardiomyopathy in aﬀected males is usually
hypertrophic with childhood onset [20]. Its course is
progressive and is the cause of death from arrhythmia or
severe heart failure, usually at 18 to 19 years of age
[20,26]. Aﬀected female relatives appear to have less
severe cardiomyopathy with mainly dilative morphology
and later onset of symptoms, and death is usually later,
at 37 to 40 years of age [20,26]. ECG may be normal in
the early stages of the disease but is pathological in all
patients at a later stage. The most frequent ﬁnding is
Wolﬀ-Parkinson-White syndrome, which is believed to
be due to a disruption of the annulus ﬁbrosus by gly-
cogen-engorged myocytes, as demonstrated in an animal
model for constitutional activation of PRKAG2, an-
other condition with pre-excitation due to glycogen
storage within cardiomyocytes [1].
Muscle biopsy shows a characteristic vacuolar
myopathy with PAS-positive inclusions in heart and
skeletal muscle myocytes. Electron micrographs show
large amounts of glycogen distorting the myoﬁbrillar
bundles, lysosomes ﬁlled with glycogen, and numerous
cylinder-shaped vacuoles full of partially degraded
Fig. 5 Left panel: SSCP pattern
of exon 2 of LAMP2 ampliﬁed
from two control DNA samples
(C1 and C2) and the patient’s
DNA (P). ds indicates double-
stranded and ss single-stranded
PCR products. Note mobility
shift in the ss population from
the patient. Right panel:
bidirectional sequence analysis
of exon 2 in LAMP2 showing
hemizygosity for a G ﬁ A
transition at position 138
leading to the change of codon
46 from TGG (Trp) to TGA
(stop)
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autophagic material. These latter ﬁndings are charac-
teristic of Danon disease. Myocardial ﬁbrosis may occur
in the course of the disease. The accumulation of gly-
cogen can be conﬁrmed biochemically and has, in the
past, led to the classiﬁcation of Danon disease as a
variant form of Pompe disease (GSD II) with lysosomal
glycogen accumulation but normal a-glucosidase [8].
The biochemical ﬁndings are in contrast to those
found in mucolipidosis II/III, another generalised lyso-
somal disorder, in which the activities of several lyso-
somal enzymes are drastically increased in serum while
being reduced in ﬁbroblasts. Therefore, Danon disease
cannot be diagnosed biochemically by measuring these
enzymes in serum.
The genetic defect has been localised to Xq24, and
some 25 mutations have been identiﬁed to date [15, 18,
22,26]. The LAMP2gene encodes LAMP2 which has a
transmembrane domain believed to project from the
lysosomal membrane into the lysosomal space. The ab-
sence of LAMP2 leads to an accumulation of autopha-
gic vacuoles, mainly in heart and skeletal muscle cells,
but also in other tissues, e.g. liver and platelets [20].
Most mutations lead to premature truncation of
LAMP2 with abolition of the transmembrane domain
(as in our case), and thus can be assumed to represent
null alleles. The more severe ‘‘neonatal form’’ of glyco-
gen storage disease with normal acid maltase is most
probably caused by mutations in a diﬀerent gene [26]. At
present, Danon disease is the only example of cardio-
myopathy and skeletal myopathy caused by a mutation
in a lysosomal structural protein rather than a lysosomal
enzyme.
Unfortunately, there is no causal therapy for Danon
disease. The therapeutic aim for patients is to prevent
progressive heart failure and to reduce the risk of ar-
rhythmias and sudden death. As the disease progresses,
the only remaining therapeutic option is cardiac trans-
plantation. Since mental retardation and skeletal
myopathy are not progressive, the prognosis after
transplantation is good [10]. The timing of cardiac
transplantation still remains diﬃcult, as exempliﬁed by
this patient. With the advent of mutation analysis it is
possible to conﬁrm the diagnosis, plan a therapeutic
regime, and oﬀer genetic counselling.
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